58607-59-3Relevant academic research and scientific papers
Pharmaceutical composition for treating glaucoma and compound 1,3,2-dioxaphospheringnes
-
, (2008/06/13)
Organo-phosphorus compounds of the general formula STR1 wherein Z is a member selected from STR2 wherein R and R' are each selected from hydrogen and lower alkyl, R designates a member selected from methyl and ethyl, and X- is an anion may be used as active ingredient in pharmaceutical and pesticidal, especially acaricidal and fungicidal, compositions of matter of low mammalian toxicity.
Synthesis and properties of 2 S [2' (N,N dialkylamino)ethyl]thio 1,3,2 dioxaphosphorinone 2 oxide and of the corresponding quaternary derivatives as potential nontoxic antiglaucoma agents
Amitai,Ashani,Grunfeld,Kalir,Cohen
, p. 810 - 813 (2007/10/05)
A new series of cyclic organophosphorus esters, 2 S [2' (N,N dialkylamino)ethyl]thio 1,3,2 dioxaphosphorinane 2 oxide and their quaternary derivatives, was synthesized and studied as potential antiglaucoma agents These compounds inhibit acetylcholinesterase (E.C. 3.1.1.7) at a bimolecular rate constant (k(i)) in the range of 103-104 M-1 min-1. Values of the affinity (K) and phosphorylation (k') rate constants for this enzyme indicate that k' is responsible for the relatively low values of k(i) as compared with similar data for the open chain analogues, O,O diethyl phosphorothiolates (106 M-1 min-1). The mammalian toxicity of the new compounds in terms of acute LD50 values in mice is 1-3 x 103 less than that of phospholine, an open chain analogue. In an initial clinical trial, one member of the new series (alkyl= C2H5) caused a significant decrease of intraocular pressure in aphakic glaucoma, while phospholine proved to be ineffective.
